These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6808721)

  • 1. Analysis of antibody production induced by allogeneic tumor cells inoculated into the anterior chamber of the eye.
    Niederkorn JY; Streilein JW
    Transplantation; 1982 Jun; 33(6):573-7. PubMed ID: 6808721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice.
    Niederkorn J; Streilein JW; Shadduck JA
    Invest Ophthalmol Vis Sci; 1981 Mar; 20(3):355-63. PubMed ID: 6782034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic analysis of intraocular allogeneic tumors in mice.
    Luckenbach MW; Streilein JW; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1985 Oct; 26(10):1368-76. PubMed ID: 3930419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
    Niederkorn JY; Streilein JW
    J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Nov; 131(5):2587-94. PubMed ID: 6415174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of immunity to intraocular tumors in mice.
    Niederkorn JY; Streilein JW
    Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenetic basis for immunologic privilege in the anterior chamber of the eye.
    Niederkorn JY; Shadduck JA; Streilein JW
    Immunogenetics; 1981; 13(3):227-36. PubMed ID: 6792066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloantigen presentation to the anterior chamber of the eye subverts specific in vitro cell-mediated immune responses.
    Whittum JA; Niederkorn JY; Streilein JW
    Transplantation; 1982 Oct; 34(4):190-5. PubMed ID: 6183804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
    Ksander BR; Mammolenti MM; Streilein JW
    Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen.
    Streilein JW; Niederkorn JY
    J Exp Med; 1981 May; 153(5):1058-67. PubMed ID: 6788883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
    Streilein JW; Niederkorn JY
    J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target.
    Al-Rammahy AK; Levy JG
    Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763
    [No Abstract]   [Full Text] [Related]  

  • 14. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens.
    Streilein JW; Niederkorn JY; Shadduck JA
    J Exp Med; 1980 Oct; 152(4):1121-5. PubMed ID: 6775039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye. I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response.
    Ksander BR; Streilein JW
    Transplantation; 1989 Apr; 47(4):661-7. PubMed ID: 2523103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconsidering the immunologic privilege and lymphatic drainage of the anterior chamber of the eye.
    Niederkorn JY; Lynch MG
    Transplant Proc; 1989 Feb; 21(1 Pt 1):259-60. PubMed ID: 2495604
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of delayed hypersensitivity to alloantigens coinjected with Langerhans cells into the anterior chamber of the eye. Abrogation of anterior chamber-associated immune deviation.
    Williamson JS; Streilein JW
    Transplantation; 1989 Mar; 47(3):519-24. PubMed ID: 2493700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.